Rutgers team, led by PI Chundawat, has been selected by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) as part of the Institute’s Project Call 5.2. Chundawat-led team will develop and validate an integrated process analytical technology (PAT) to automate continuous monitoring of critical drug quality attributes like N-glycosylation during upstream biomanufacturing of therapeutic proteins like monoclonal antibodies. The research project is titled “An Integrated Platform for Fully Automated, Continuous, & Real-Time Multi-Attributes Monitoring of Upstream Processes for Glycosylated Monoclonal Antibodies Production”. Other project participants include Agilent Technologies, Endress+Hauser, and University of Delaware. The summary can be read in the Press Release via the following link: Link
The $1.5 million project cost includes $750k research grant from NIIMBL with remainder in-kind support including donated equipment/supplies & other cost-share support from industry and university partners. The project, part of 14 new projects sponsored by NIIMBL, will be completed over a 18 month period starting in April 2023.